The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues

Trial Profile

The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Cobicistat; Darunavir
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms DOLBI
  • Most Recent Events

    • 13 Nov 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 13 Nov 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
    • 27 Oct 2017 Results (n=53) presented at the 16th European AIDS Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top